Company profile
Generate Biomedicines, Inc.
NASDAQ:GENBBiotechnology: Pharmaceutical Preparations
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07276724 | phase3 | recruiting | 2025-12-03 | 2028-12-01 | Generate Biomedicines | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) |
| NCT07359846 | phase3 | recruiting | 2026-01-20 | 2029-01-01 | Generate Biomedicines | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) |
| NCT07116889 | phase1 | active_not_recruiting | 2023-12-12 | 2027-05-01 | Generate Biomedicines | A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD |
| NCT07484022 | phase1 | recruiting | 2026-06-01 | 2027-06-01 | Generate Biomedicines | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer |
| NCT07050511 | phase1 | completed | 2023-07-18 | 2024-11-22 | Generate Biomedicines | Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants |
FDA applications (0)
No records yet.